Table 3.
Receiver operating characteristics (ROC) analysis demonstrating the area under the curve (AUC) of each individual biomarker as well as a selected combination of biomarkers, representing their discriminative ability regarding long-term continuation vs. discontinuation of vedolizumab treatment.
| Biomarker | AUC [95% CI] | Sensitivity (%) | Specificity (%) | p-Value |
|---|---|---|---|---|
| Individual biomarkers | ||||
| C1M | 0.85 [0.72–0.98] | 76 | 87 | <0.001 |
| CPa9-HNE | 0.81 [0.66–0.96] | 100 | 53 | <0.001 |
| C3M | 0.79 [0.62–0.95] | 71 | 87 | 0.001 |
| C3M/PRO-C3 | 0.78 [0.60–0.95] | 76 | 80 | 0.002 |
| C4M | 0.77 [0.60–0.93] | 76 | 73 | 0.002 |
| PRO-C4 | 0.77 [0.59–0.94] | 71 | 80 | 0.003 |
| C6Ma3 | 0.75 [0.58–0.92] | 53 | 93 | 0.004 |
| C4M/C4G | 0.74 [0.56–0.92] | 88 | 60 | 0.009 |
| PRO-C4/C4G | 0.72 [0.54–0.90] | 82 | 53 | 0.015 |
| CPa9-HNE/C4G | 0.70 [0.52–0.89] | 100 | 40 | 0.034 |
| PRO-C4/C4M | 0.49 [0.28–0.70] | 100 | 13 | 0.927 |
| PRO-C3 | 0.45 [0.24–0.66] | 35 | 87 | 0.623 |
| C4G | 0.44 [0.23–0.65] | 35 | 67 | 0.563 |
| Combined biomarkers | ||||
| [PRO-C4, C6Ma3] | 0.84 [0.70–0.98] | 65 | 93 | <0.001 |
| [C3M, C6Ma3] | 0.83 [0.69–0.97] | 71 | 87 | <0.001 |
| [PRO-C4, C3M/PRO-C3] | 0.81 [0.65–0.97] | 100 | 53 | <0.001 |
Abbreviations: AUC, area under the curve; CI, confidence interval.